The data about the ability of various substances to cause definite reactions in biological objects are adduced, and, in particular, about the efficacy of a small doses of antitumoral chemopreparations in experiment. The results of investigation of the application efficacy of various doses of immunomodulating agents, such as arbisol, nucleoplat, the substrate from gram-negative bacteria Yersinia enterocolitica, antitumoral vaccine from the tumoral cells are presented for the cancer chemotherapy. While application of super-small doses of an antitumoral vaccine there was noted statistically significant inhibition of tumoral growth.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.
Cancer Sci
January 2025
Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.
CBA-1205 is a novel humanized antibody targeting delta-like 1 homolog (DLK1) that enhances antibody-dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma and neuroblastoma. CBA-1205 demonstrates potent antitumor activity in multiple tumor models, making it a potential treatment option for DLK1-expressing cancers.
View Article and Find Full Text PDFPotential therapeutic applications of medical gases in cancer treatment.
Med Gas Res
June 2025
Research Department, Plovdiv Medical University, Plovdiv, Bulgaria.
Medical gases were primarily used for respiratory therapy and anesthesia, which showed promising potential in the cancer therapy. Several physiological and pathological processes were affected by the key gases, such as oxygen, carbon dioxide, nitric oxide, hydrogen sulfide, and carbon monoxide. Oxygen targets shrinking the tumor via hyperbaric oxygen therapy, and once combined with radiation therapy it enhances its effect.
View Article and Find Full Text PDFMetformin as an immunomodulatory agent in enhancing head and neck squamous cell carcinoma therapies.
Biochim Biophys Acta Rev Cancer
January 2025
Department of Dental Materials, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, No. 117 Nanjing North Street, Heping District, Shenyang 110002, Liaoning, China. Electronic address:
Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge due to its aggressive behavior and poor prognosis, making the development of novel therapeutics with enhanced efficacy and minimal side effects critical. Metformin, a widely used antidiabetic agent, has recently emerged as a potential adjunctive therapy for HNSCC, exhibiting both direct anti-tumor and immunomodulatory effects. This review comprehensively explores the multifaceted role of metformin in shaping the tumor immune microenvironment within HNSCC.
View Article and Find Full Text PDFInjectable hydrogel-assisted local lipopolysaccharide delivery improves immune checkpoint blockade therapy.
Acta Biomater
January 2025
Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, PR China; National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin, PR China; International Center of Future Science, Jilin University, Changchun, Jilin, PR China; State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin, PR China. Electronic address:
Tumor-associated macrophages (TAMs) significantly influence the clinical outcomes of immune checkpoint blockade (ICB) therapy. Strategies aimed at reprogramming TAMs from the immunosuppressive M2 phenotype to the pro-inflammatory M1 phenotype hold promise for enhancing ICB efficacy. Lipopolysaccharide (LPS), a potent Toll-like receptor 4 (TLR4) ligand, can reprogram TAMs toward an M1 phenotype.
View Article and Find Full Text PDFPhase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.
J Immunother Cancer
January 2025
Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Purpose: BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses.
Materials And Methods: This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported here are single-center results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!